Premium
Who writes dermatology randomized controlled trials? The need to specify the role of medical writers
Author(s) -
Steele L.,
Lee H. L.,
Earp E.,
Hong A.,
Thomson J.
Publication year - 2021
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14711
Subject(s) - randomized controlled trial , alternative medicine , medicine , clinical trial , dermatology , medical literature , medline , family medicine , surgery , pathology , political science , law
Summary Medical writers may make major contributions to the preparation of a manuscript, but are not listed as authors. We assessed the prevalence, affiliation and role of medical writers in dermatology randomized controlled trials (RCTs) published in 2019 in the top 7 medical and top 10 dermatology journals. Medical writers were identified in 39/83 trials (47%), all of which were exclusively industry‐funded trials (39/47, prevalence 83%). Most studies stated their role as ‘medical writing support’ and/or ‘editorial assistance’ (35/39, 90%), but when more information was provided, four studies specified first draft preparation (50% of RCTs in general medical and 1.3% of RCTs in dermatology journals). Medical writers are common in dermatology trials but their role is often vaguely stated. In April 2020 the British Journal or Dermatology and Clinical and Experimental Dermatology adopted CRediT (Contributor Roles Taxonomy), which describes contributions of authors and may help clarify who writes trial manuscripts.